BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Paloxi: Phase II data

A Phase II trial in 60 multiple myeloma (MM) patients undergoing multiday, high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) showed that IV palonosetron for 30 min. before starting HDT improved emesis and nausea control. Specifically, 98% of patients achieved complete response as...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >